Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
READ-UP
MALARIA
Framework programme: 6
Call: 3
Project number:
LSHP-CT-2005-018602
EC contribution: € 2 000 000
Duration: 36 months
Type: STREP
Starting date: 1 December 2005
Graphic element Redox Antimalarial Drug discovery
Keywords: Human parasitology; pharmaceutical chemistry; malaria; drug candidate; hit-to-lead optimisation; innovative Redox concept; developing countries

Summary:

The READ-UP project aims at identifying antimalarial drug candidates (one candidate and two back-ups). The project will begin with a hit identified in the first series, enlarging it, and designing other series through the different steps of drug discovery and hit-to-lead optimisation from the pilot scale production towards pre-clinical studies.

Artemisinin, the natural antimalarial product, and its derivatives are increasingly important in the treatment of drug-resistant malaria as they are the most potent antimalarials available, rapidly killing all blood stages of the malaria parasite. Artemisinins contain an endoperoxide bridge which plays a key role in the antimalarial activity with a mode of action starting from radical transient species initiated by the cleavage of this bridge. The READ-UP project starts from the unique mode of action of artemisinins to develop a completely new approach: initiate radical transient species within the parasitised red blood cell in such a way that no endoperoxide bridge is required.

Background:

Malaria remains one of the most devastating diseases of the developing world, causing more than 1 million deaths and 300-500 million clinical cases each year. Although four Plasmodium species infect humans (P. falciparum (P. f.), P. vivax, P. ovale and P. malariae), most deaths are caused by the severe complications of P. f. malaria. Malaria-related morbidity and mortality are increasing, mainly as a consequence of drug resistance as observed with the two most widely used antimalarial drugs: chloroquine and sulfadoxine-pyrimethamine. To combat malaria, new drugs are urgently needed.

In this context, the READ-UP project brings together public organisations and SMEs to drive a research project aimed at identifying a new drug candidate for malaria. Starting from one series with antimalarial activity, which was created by a public laboratory of the consortium using a new approach, the project, coordinated by a pharmaceutical SME, will realise hit-to-lead optimisation through molecular modelling, testing of new chemical entities in vitro and in vivo and pharmacological, pharmacokinetics, toxicological and mechanisms studies.

Aim:

Following the drug discovery process until the pilot-scale production, the objective is to propose one antimalarial drug candidate with two back-ups for further pre-clinical studies.

Expected results:

An initial series of new stable compounds has been developed by UPS. In a first synthetic series, several compounds presented anti-plasmodial properties and preliminary in vitro and in vivo studies led to the identification of one hit. Based on the excellent in vitro and in vivo results already obtained, the READ-UP project will develop new structural analogues using the same innovative approach. The in vitro and in vivo results obtained will be further improved by the application of optimisation techniques, through the ‘Drug Discovery’ process that the READ-UP partners will implement. The project aims at enlarging this first series and designing other series to identify new antimalarial drug candidates (one drug candidate and two back-ups) through the different steps of drug discovery and hit optimisation. Moreover, the READ-UP innovative strategy should allow designing chemically stable compounds, which may have a longer duration of action in vivo.

Potential applications:

Application of READ-UP scientific breakthroughs into approved new medicines.

Coordinator:

Serge Petit
Idéalp’ Pharma/IDEALP
Bât. CEI – 66
Bd Niels Bohr - BP 2132
69603 Villeurbanne Cedex

France
Tel: +33 4 37 48 88 00
Fax: +33 4 78 93 56 53
Website: http://www.idealp-pharma.com

Partners:

Principal
Scientific
Participants
Official Address Other Information
2
Françoise Nepveu
Université Paul Sabatier and
Institut de Recherche pour le Développement
Laboratoire ‘Pharmacochimie des
Substances Naturelles et Pharmacophores Redox’
Université Paul Sabatier, Toulouse 3
Faculté de Pharmacie,
31 062 Toulouse Cedex 9
France
Tel: +33 (0)5 61 55 66 13
Fax: +33 (0)5 61 55 64 70
E-mail: nepveu@cict.fr
Website: http://www.ups-tlse.fr
 
3
Paolo Arese
Dipartimento Di Genetica,
Biologia E Biochimica,
Universita Di Torino
Via Santena 6 bis
10126 Torino
Italy
Tel: +39 011 6706686
Fax: +39 011 6706590
E-mail: paolo.arese@unito.it
4
Livia Vivas
London University
London School of Hygiene & Tropical Medicine
University of London
Department of Hygiene and Tropical Diseases
Keppel Street
UK-London WC1E 7HT
Tel: +44 (0)02-7927 2345
Fax: +44 (0)02-7637 4314
E-mail: livia.vivas@lshtm.ac.uk
Website: http://www.lshtm.ac.uk
5
Leonardo Basco
Organisation de Coordination
pour la lutte contre les Endémies
en Afrique Centrale
OCEAC-IRD
BP 288
Yaoundé
Cameroun
Tel: +237 23 2232/237786
Fax: +237 23 0061
E-mail: leonardo.basco@ibaic.u-psud.fr
6
Laurence Touchard-Nicod
ACIES
69, rue de la République
69002 Lyon
France
Tel: +33 (0)4 78 92 40 00
Fax: +33 (0)4 78 92 40 01
E-mail: readup@acies.fr
Website: http://www.acies.fr

 
 
top
Graphic element